Santen Pharmaceutical Co Ltd at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 10, 2022 / NTS GMT
Seiji Wakao - JPMorgan Chase & Co, Research Division - VP

Good afternoon, everyone. Welcome to the JPMorgan Healthcare Conference. I'm Seiji Wakao, Japan pharma analyst in JPMorgan. And it's my pleasure to introduce CEO, Taniuchi, CEO of Santen Pharmaceutical, and welcome him to the conference. Well then, let me turn it over to Taniuchi-san. Taniuchi-san, please go ahead.

Shigeo Taniuchi - Santen Pharmaceutical Co., Ltd. - President, CEO & Representative Director

Thank you very much. Hello, everyone, and good morning, and good afternoon. I'm Shigeo Taniuchi, President and CEO of Santen. I'm very pleased to join JPMorgan Healthcare Conference this year again. I'm very excited by having an opportunity to talk about strategy update in following slides.

Please go to next page, Slide #2. Our mission, as you know, Santen is a leading ophthalmology company focusing on eye health for more than 130 years. Commitment on social contribution through eye health is embedded into our every strategy and our every employee at front end as DNA. In this (inaudible) I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot